The goal of this clinical trial is to find out if a gut cleaning using Rifaximin works as well as the usual treatment with Neomycin and Metronidazole to prevent infections after colon surgery. The study includes adult patients who will have colon surgery.
The main question it aims to answer are:
-Does the Rifaximin treatment prevent surgical site infections as well as the Neomycin/Metronidazole treatment?
Other things the study will look at:
* How often infections happen, stratified on how deep they are, the type of surgery the patients got, or if bowel cleaning was done before surgery.
* How many people will die after surgery
* How long people stay in hospital
Participants will:
* Take either Rifaximin or Neomycin/Metronidazole one day before surgery to clean their gut
* Keep a diary until the surgery to record medication intake and any side effects
* Be contacted by phone 30 days after surgery to ask about their condition and any side effects,

Start Date01 Jun 2026

Sponsor / Collaborator

Universität Luzern

NCT07203846

/ Not yet recruitingPhase 4IIT

Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)

The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.

Start Date01 Jan 2026

Sponsor / Collaborator

Collegium Medicum

NCT07209371

/ RecruitingPhase 2IIT

Rifaximin Versus No Intervention in Patients With IgA Monoclonal Gammopathy of Undetermined Significance

This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgA MGUS.

Start Date19 Dec 2025

Sponsor / Collaborator

Fred Hutchinson Cancer Research Center

[+1]

100 Clinical Results associated with Rifaximin

100 Translational Medicine associated with Rifaximin

100 Patents (Medical) associated with Rifaximin

1,704

Literatures (Medical) associated with Rifaximin

31 Dec 2025·Virulence

Differences in virulence and drug resistance between Clostridioides difficile ST37 and ST1 isolates

Article

Author: Qiang, Cuixin ; Qin, Pu ; Zhang, Huimin ; Wang, Weigang ; Zhao, Jianhong ; Li, Zhirong ; Yang, Yaxuan ; Yang, Jing ; Zhao, Min ; Yang, Huimin ; Niu, Yanan ; Ouyang, Zirou ; Zhao, Jiafeng

One of the most common hospital-acquired infections is caused by toxigenic Clostridioides difficile. Although C. difficile ST37 only produces a functional toxin B, it causes disease as severe as that caused by hypervirulent ST1. We aim to compare the differences in virulence and drug resistance between ST37 and ST1 isolates. We conducted whole-genome sequencing on ST37 and ST1 isolates, analyzing their type-specific genes, and the distribution and mutation of genes related to virulence and antibiotic resistance. We compared the in vitro virulence-related phenotypes of ST37 and ST1 isolates, including: TcdB concentration, number of spores formed, aggregation rate, biofilm formation, swimming diameter in semi-solid medium, motility diameter on the surface of solid medium, and their resistance to 14 CDI-related antibiotics. We detected 4 ST37-specific genes related to adherence, including lytC, cbpA, CD3246, and srtB. We detected 97 virulence-related genes in ST37 isolates that exhibit genomic differences compared to ST1. ST37 isolates showed increased aggregation, biofilm formation, and surface motility compared to ST1 in vitro. Chloramphenicol resistance gene catQ and tetracycline resistance gene tetM are present in ST37 but absent in ST1 strains. The resistance rates of ST37 to chloramphenicol and tetracycline were 45.4% and 81.8%, respectively, whereas ST1 isolates were sensitive to both antibiotics. ST1 was more resistant to rifaximin than ST37. ST37 isolates showed stronger aggregation, biofilm formation and surface motility, and had higher resistance rates to chloramphenicol and tetracycline. ST1 isolates showed stronger ability to produce toxin and sporulation, and was highly resistant to rifaximin.

01 Dec 2025·INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Advances in the Medical Treatment of Clostridioides difficile Infection

Review

Author: Kraft, Colleen ; Mehta, Nirja ; Johnson, Stuart

Clostridioides difficile medical management has changed significantly over the past decade with emphasis on preventing recurrent infection. This review compares current guidelines on the treatment of initial, recurrent, fulminant, and pediatric C difficile infection (CDI) and evaluates the mechanisms and clinical use of available antibiotics for CDI. C difficile has complex resistance mechanisms to vancomycin, fidaxomicin, and metronidazole which may play a role in treatment outcomes. Antibiotics such as tigecycline and rifaximin as well as monoclonal antibodies against toxin B may play a role in adjunctive therapy. Additional therapies under development include new narrow therapeutic antibiotics.

01 Dec 2025·Current Neurology and Neuroscience Reports

Hepatic Encephalopathy: Current Thoughts on Pathophysiology and Management

Review

Author: Chakravarty, Ambar ; Pan, Kausik ; Sen, Barun Kumar

PURPOSE OF REVIEW:

This review highlights the causes, types and clinical staging of hepatic encephalopathy (HE). Current concepts on the probable pathogenetic mechanisms and currently practiced therapeutic options are discussed.

RECENT FINDINGS:

HE may be covert and overt. Also known as minimal HE. Covert HE, where there are behavioral abnormalities and impairment in activities of daily living with intact sensorium. The pathophysiology of HE remains poorly understood. There is disturbance of the urea cycle due to liver disease leading to increased production of ammonia. The ammonium ion enters the astrocytes along with glutamate (converted to glutamine by ammonia) and myo-inositol, thereby increasing the osmolality of the astrocytic cytoplasm. This osmotic gradient results in accumulation of water inside the astrocytes resulting in cerebral edema and increase in brain volume. Additionally, current research has noted the role of cerebral oxidative/nitrosative stress and the synergistic effects of increased cerebral ammonia and alteration in neurotransmitters, neurometabolites, and cortical excitability due to systemic inflammation. In advanced liver disease with systemic infection or inflammation, neuroinflammatory processes play significant role in the development of HE. Inflammatory cytokines like TNF-α, IL-6, IL-17 in presence of hyperammonemia have been found to induce neurotoxicity of ammonia by passing through the blood brain barrier and causing enlarged/swollen pale astrocytes, resulting in HE. Disrupted enterohepatic circulation in end stage liver disease also causes elevation of bile acids which induces neuroinflammation. Manganese and zinc play as co-factors of enzymatic reaction. These metal deposition causes multiple psychomotor symptoms observed in HE. The gut environment has a major impact on brain function in patients with HE. Toxins such as ammonia and inflammatory cytokines produced by this impaired intestinal flora access the circulation through porto-systemic anastomoses and exacerbate or precipitate HE. Finally, as a result of recurrent cerebral edema from astrocytic dysfunction and neuroinflammation, permanent neurodegeneration occurs with cognitive decline and motor disturbances, especially parkinsonian features and gait disturbances. This is the stage of chronic hepatic encephalopathy. Currently L-ornithine L-aspartate (LOLA) is being used to lower the ammonia level by stimulating the urea cycle. HE comprises a broad spectrum of neurological and/or psychiatric abnormalities caused by hepatic insufficiency and/or portal-systemic shunting in the absence of any other causes of brain dysfunction. HE may be caused or precipitated by several factors like infections, intoxications and drugs. The encephalopathic features may be covert or overt. The pathogenetic mechanisms for HE may be different. In the presence of liver disease, HE primarily results from disturbed urea cycle with hyperammonemia causing astrocytic swelling and cerebral edema. Porto-systemic anastomoses with intact liver function can cause HE by allowing ammonia and other toxins produced by the gut microbial flora and allowing these to bypass detoxification by the liver and exposing the brain to their harmful effects. Principles of therapy are twofold. First protecting the liver and the brain from gut generated ammonia and other toxins by ensuring smooth bowel function and avoiding stagnation with the use of osmotic laxatives like lactulose or lactitol and also reducing the gut microbial load with use of anti-bacterials/bacteriophages like neomycin and rifaximin along with metronidazole. Second, reducing the already generated cerebral edema by use of mannitol and appropriate ventilatory support. Currently L-ornithine L-aspartate (LOLA) is being used to reduce the ammonia load to the liver. LOLA is a stable compound formed from two amino acids. L-ornithine plays a crucial role in stimulating the urea cycle, leading to a reduction in ammonia levels. Both L-ornithine and L-aspartate serve as substrates for the enzyme glutamate transaminase, and their administration results in elevated glutamate concentrations. Ammonia is subsequently utilized in the conversion of glutamate to glutamine through the action of glutamine synthetase. Finally in resistant cases the use of liver transplant needs to be considered. Alternatively extracorporeal liver assist devices may be used like Molecular Adsorbent Recirculating System (MARS) or Single-Pass Albumin Dialysis (SPAD).

107

News (Medical) associated with Rifaximin

26 Nov 2025

·www.fiercepharma.com

Medicare unveils price reductions for 15 drugs, including Novo's semaglutide

Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., said that new Inflation Reduction Act-mandated Medicare prices for 15 prescription drugs "stand in stark contrast " to "counterproductive 'deals' we saw before," under the Biden administration. The U.S. has revealed price reductions for the second round of prescription drugs negotiated by the Centers for Medicare & Medicaid Services (CMS) through the Inflation Reduction Act (IRA). Headlining the list of 15 treatments that will undergo price reductions in 2027 are Novo Nordisk’s semaglutide products, Ozempic and Wegovy.The negotiated price for Ozempic is $274 per month compared to the current list price of $959. Meanwhile, the new price for higher doses of Wegovy will be $385 per month, according to a CMS document. The adjusted prices are what Medicare will pay drugmakers for the medicines.Prices for drugs on the list have been slashed by between 38% and 85%, according to CMS. The discounts will cut Medicare’s costs for the 15 drugs by 44% and save taxpayers roughly $12 billion per year from prior spending levels, the agency said.While pushing for lower drug prices through his Most Favored Nation (MFN) plan, President Donald Trump has largely downplayed the IRA as a tool for achieving them. The program was established in 2022 under President Joe Biden. Medicare price reductions go into effect at the start of next year for the initial round of 10 drugs selected for negotiations.“This year’s results stand in stark contrast to last year’s,” said CMS Administrator Mehmet Oz, M.D., in a release. “Using the same process with a bolder direction, we have achieved substantially better outcomes for taxpayers and seniors in the Medicare Part D program—not the modest or even counterproductive ‘deals’ we saw before.”Next year, another round of 15 drugs will be selected for price reductions that will go into effect in 2028. That will be followed by a round of 20 drugs that will see price reductions in 2029.On the list of newly announced price reductions are two drugs from AbbVie. Antipsychotic treatment Vraylar was slashed from a list price of $1,376 per month to $770, while irritable bowel syndrome medicine Lynzess was adjusted from $539 to $136 per month. Also on the list are two drugs: Boehringer Ingelheim. Lung disease drug Ofev will see a reduction from $12,622 to $6,350 per month, while the price of Type 2 diabetes treatment Tradjenta was cut from $488 to $78 per month.GSK has two drugs on the list as well, both to treat COPD and asthma. The price of Breo Ellipta was reduced from $397 to $67 per month, while the monthly price of newer Trelegy Ellipta was cut from $654 to $175.The most expensive drugs on the list are cancer treatments, topped by Bristol Myers Squibb’s multiple myeloma treatment Pomalyst, which will see a monthly price slash from $21,744 to $8.650. Pfizer’s breast cancer drug Ibrance will be cut from $15,741 to $7,871 per month, according to the CMS document.The price for AstraZeneca’s blood cancer drug Calquence has been cut from $14,228 to $8,600, while Pfizer and Astellas have seen the monthly price of their prostate cancer treatment Xtandi reduced from $13,480 to $7,004.Also slashed were prices for Salix’s gastrointestinal treatment Xifaxan, from $2,696 to $1,000 per month; Amgen’s psoriasis drug Otezla, from $4,722 to $1,650; Merck’s Type 2 diabetes treatments Januvia and Janumet, from $526 to $80 per month; and Teva’s movement disorders drug Austedo, which goes from $6,623 to $4,093. As for the price reductions for the highest-profile drugs on the list, Ozempic and Wegovy, a Novo spokesperson said that the company continues “to have serious concerns about the Inflation Reduction Act’s impact on patients” and that it remains “opposed to government price setting.”“We have seen that government price setting has not translated to lower out-of-pocket costs for patients and can lead to a loss of coverage for medications and higher insurance premiums,” the spokesperson said. “We will continue to work with stakeholders and policymakers to expand affordable access to our medicines through both government and commercial insurance plans.”

26 Nov 2025

·www.biopharmadive.com

CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs

Medicare will pay billions of dollars less in 2027 for 15 drugs, including major medicines for cancer, asthma and metabolic conditions, after completing the second annual round of price negotiations required under the Inflation Reduction Act.The Centers for Medicare and Medicaid Services on Tuesday announced the final prices, which, if they had been in place in 2024, would have reduced aggregate spending by 44%, or $12 billion. Beneficiaries out-of-pocket spending would have been reduced $685 million, the CMS said.The announcement concludes three rounds of negotiations between the agency and drugmakers, who made offers and counteroffers with a review of evidence supporting their respective proposals. CMS said the prices of seven were reached based on a revised counteroffer from the respective drugmakers. In seven other cases, the company accepted a written final offer from CMS.The price for semaglutide, the active ingredient in Novo Nordisks blockbuster obesity drug Wegovy and diabetes shot Ozempic, was preannounced in an Oval Office press conference with President Donald Trump. The administration is seeking to equalize prices between the U.S. and other industrialized nations.The drugs included on Medicare's latest round of price negotiations.DrugManufacturerNegotiated Price (30 day supply)List Price 20242024 Gross Covered CostEnrollees Who Used Drug in 2024SemaglutideNovo Nordisk$274$959$15.2 billion2.3 millionTrelegy ElliptaGSK$175$654$5.3 billion1.3 millionXtandiAstellas/Pfizer$7,004$13,480$3.4 billion35,000PomalystBristol Myers Squibb$8,650$21,744$2.2 billion14,000OfevBoehringer Ingelheim$6,350$12,622$2.1 billion24,000IbrancePfizer$7,871$15,741$2 billion16,000LinzessAbbVie$136$539$2 billion632,000CalquenceAstraZeneca$8,600$14,228$1.7 billion15,000AustedoTeva$4,093$6,623$1.7 billion27,000Breo ElliptaGSK$67$397$1.4 billion626,000XifaxanSalix$1,000$2,696$1.2 billion105,000VraylarAbbVie$770$1,376$1.1 billion118,000TradjentaBoehringer Ingelheim$78$488$1.1 billion274,000JanumetMerck & Co.$80$526$1.1 billion239,000OtezlaAmgen$1,650$4,722$1 billion31,000SOURCE: Centers for Medicare and Medicaid ServicesThe latest round also includes the diabetes drugs Tradjenta and Janumet; cancer medicines Xtandi, Pomalyst, Ibrance and Calquence; respiratory therapies Trelegy, Ofev, and Breo; and the gastrointestinal treatments Linzess and Xifaxan. Also on the list are Austedo, for irregular body movements; Vraylar, for depression; and Otezla, for psoriasis.The Inflation Reduction Act for the first time allowed for price negotiations under Medicare, which began covering pharmacist-dispensed drugs in 2006 under whats known as Part D. Prices for 10 drugs set under the first round of negotiations conducted in 2024 will go into effect in 2026, followed by these 15 in 2027.To be eligible for price negotiations, the drugs must be single-source, typically meaning branded products not subject to competition from generics or biosimilars.In 2026, Medicare will negotiate the prices for an additional 15 high-expenditure drugs, which would include not just the pharmacist-dispensed drugs covered by Part D but also the physician-administered drugs covered by Part B. The latter group could include high-priced biological drugs that can be delivered only through intravenous infusions. '

Accelerated Approval

20 Nov 2025

·investors.edgewisetx.com

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

BOULDER, Colo., Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions, including marketing, sales, commercial operations, market access, trade and business development. "We are thrilled to welcome Chris to our Board of Directors," said Kevin Koch, Ph.D., President and Chief Executive Officer. "His commercial expertise and launch leadership will be critical as we prepare for our first commercial launch in Becker muscular dystrophy and advance our cardiovascular asset to Phase 3. Prior to joining the Edgewise Board, Mr. Martin served as Chief Commercial Officer for Verona Pharma, which was acquired by Merck & Co. for approximately $10 billion in October of 2025. As CCO, Mr. Martin was responsible for building the commercial organization and launch strategy for the company's first product launch, Ohtuvayre® (ensifentrine). Prior, he served as Executive Director of Marketing at SK Life Science which is focused on developing novel therapeutics for central nervous system conditions. Mr. Martin was instrumental in developing the commercial and marketing strategy and the framework for launching their first commercial product, XCOPRI® (cenobamate tablets). Until its acquisition by Melinta Therapeutics, Mr. Martin was Head of Marketing at Cempra where he led the development and launch strategy for the company's first product, solithromycin. Prior to Cempra, he was at Salix Pharmaceuticals for 10 years in roles of increasing responsibility and led the Xifaxan® marketing team during the company's acquisition by Valeant Pharmaceuticals. Mr. Martin received a Bachelor of Science in Financial Management from Clemson University. About Edgewise Therapeutics Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, Edgewise's product candidates and programs, including sevasemten, EDG-7500 and EDG-15400; statements regarding Edgewise's ability to commercialize sevasemten; statements regarding Edgewise's ability to advance its cardiovascular asset to Phase 3; and statements by Edgewise's President and Chief Executive Officer. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon Edgewise's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with Edgewise's limited operating history, its products being early in development and not having products approved for commercial sale; risks associated with Edgewise not having generated any revenue to date; Edgewise's ability to achieve objectives relating to the discovery, development and commercialization of its product candidates, if approved; Edgewise's need for substantial additional capital to finance its operations; Edgewise's substantial dependence on the success of sevasemten and EDG-7500; Edgewise's ability to develop and commercialize sevasemten, EDG-7500 and EDG-15400; risks related to Edgewise's clinical trials of its product candidates not demonstrating safety and efficacy; risks related to Edgewise's product candidates causing serious adverse events, toxicities or other undesirable side effects; the outcome of preclinical testing and early clinical trials not being predictive of the success of later clinical trials and the risks related to the results of Edgewise's clinical trials not satisfying the requirements of regulatory authorities; delays or difficulties in the enrollment and/or maintenance of patients in clinical trials; risks related to failure to capitalize on other indications or product candidates; risks related to competition; risks relating to interim, topline and preliminary data from Edgewise's clinical trials changing as more patient data becomes available; risks related to failure to develop a proprietary drug discovery platform; risks related to exposure to additional risk if we develop sevasemten and potential other programs in connection with other therapies; risks related to production of drugs by Edgewise's third-party manufacturers; risks related to changes in methods of product candidate manufacturing or formulation; risks related to not achieving adequate market acceptance; risks related to the patient population for our product candidates having a small patient population; risks related to the regulatory approval processes of domestic and foreign authorities being lengthy, time consuming and inherently unpredictable; risks relating to disruptions at the FDA, the SEC and other government agencies; risks relating to Edgewise's ability to attract and retain highly skilled executive officers and employees; Edgewise's ability to obtain and maintain intellectual property protection for its product candidates; Edgewise's reliance on third parties; risks related to future acquisitions or strategic partnerships; risks related to general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that Edgewise files from time to time with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Edgewise assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-appoints-commercial-biotech-executive-christopher-martin-to-its-board-of-directors-302620999.html SOURCE Edgewise Therapeutics

Phase 1Phase 2Executive ChangeAcquisition

100 Deals associated with Rifaximin

External Link

KEGG	Wiki	ATC	Drug Bank
D02554	Rifaximin	D06AX11 A07AA11	DB01220

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperammonemia	Japan	ASKA Pharmaceutical Co., Ltd.	28 Sep 2016
Irritable bowel syndrome with diarrhea	United States	Salix Pharmaceuticals, Inc.	27 May 2015
Hepatic Encephalopathy	Australia	Norgine Pty Ltd.	17 May 2012
Turista	United States	Salix Pharmaceuticals, Inc.	25 May 2004
Diarrhea	China	Alfa Wassermann SpA	23 Dec 2002
Irritable Bowel Syndrome	China	Alfa Wassermann SpA	23 Dec 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diverticulitis	Phase 3	France	Alfasigma SpA	02 Jul 2018
Diverticulitis	Phase 3	Germany	Alfasigma SpA	02 Jul 2018
Diverticulitis	Phase 3	Italy	Alfasigma SpA	02 Jul 2018
Diverticulitis	Phase 3	Netherlands	Alfasigma SpA	02 Jul 2018
Diverticulitis	Phase 3	Spain	Alfasigma SpA	02 Jul 2018
Diverticulitis	Phase 3	United Kingdom	Alfasigma SpA	02 Jul 2018
Ascites	Phase 3	France	Alfasigma SpA	05 Jun 2018
Fibrosis	Phase 3	France	Alfasigma SpA	05 Jun 2018
Spontaneous bacterial peritonitis	Phase 3	France	Alfasigma SpA	05 Jun 2018
Crohn Disease	Phase 3	United States	Bausch Health Americas, Inc.	21 Aug 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03069131 (Pubmed \| J Hepatol)	Phase 3	-	152	Rifaximin 550 mg BID	snarbvjjry(tnyyavuvfn) = vuswcsnsec juhkjswiiy (fiapktbfxl, 43.5 - 67.8) View more	Negative	01 Dec 2025
				Placebo BID	snarbvjjry(tnyyavuvfn) = zkizvhohhc juhkjswiiy (fiapktbfxl, 56.2 - 78.7) View more
NCT06852274 (Pubmed \| Int J Colorectal Dis)	Not Applicable	Diverticulosis, Colonic	70	Clostridium butyricum CBM588	nqkbuhzzuz(mxrozuvrty) = xuztzmsnik gfmoasvhgn (kfglohzate ) View more	Positive	18 Oct 2025
				Rifaximin	nqkbuhzzuz(mxrozuvrty) = xmlnzviiuw gfmoasvhgn (kfglohzate ) View more
MDS2025	Phase 2	Dyskinesia, Drug-Induced	16	Rifaximin	wlwzsmwnqn(fbbxojhkvc) = tjkxkmosmc myegxfrodj (anptnalynz ) View more	Negative	05 Oct 2025
				Placebo	wlwzsmwnqn(fbbxojhkvc) = daspqwuncz myegxfrodj (anptnalynz ) View more
NCT04249622 (CTgov)	Phase 2	HER2 Positive Breast Cancer	20	Questionnaire Administration+Rifaximin (Arm I (Rifaximin, Pertuzumab-based Chemotherapy))	heywsibcrp = hnsyobkewl zhaiwoqchi (cbzzdlhlhg, mbbdbllmoo - gaqsvwphmm) View more	-	07 Aug 2025
				Questionnaire Administration (Arm II (Pertuzumab-based Chemotherapy))	foxwjfqqxu = gqoguucamq evmnqzcayl (efsvyeywmf, wvtzucsntu - lojhdrahto) View more
Company_Website Manual	Not Applicable	Hepatic Encephalopathy	-	Xifaxan	oajebmmqqo(dscomnjxsd): P-Value = <0.05	Positive	06 May 2025
				lactulose
NCT03219528 (CTgov)	Phase 4	Irritable Bowel Syndrome	74	Rifaximin 550 MG (Rifaximin)	wurdpmsyhy(pirqzuodgk) = kzoddcaauj vmrvepxypw (vuwqyrvxbz, 1.8) View more	-	27 Apr 2025
				Low FODMAP Diet (Low FODMAP Group)	wurdpmsyhy(pirqzuodgk) = cvxwucokqe vmrvepxypw (vuwqyrvxbz, 1.6) View more
NCT05098028 (CTgov)	Phase 2	Hemoglobin SC Disease \| Anemia, Sickle Cell	44	Low Dose Rifaximin ER (Low Dose Rifaximin ER)	lafytqeqga(xjbsgoetmx) = leguntfuud hpsssrbemq (jfxggbehce, 86.3) View more	-	19 Sep 2024
				High Dose Rifaximin ER (High Dose Rifaximin ER)	lafytqeqga(xjbsgoetmx) = odzioylnqe hpsssrbemq (jfxggbehce, 58.4) View more
PHASE II TRIAL OF RIFAXIMIN (DDW 12024 \| DDW 22024 \| DDW 32024 \| DDW 42024)	Phase 2	HER2 Positive Breast Cancer HER2 positive	20	Rifaximin 550 mg BID	whcvsogziq(gppjpqpocj) = xasecsdpfq nhuhqxunoz (banyegjkyv ) View more	Positive	20 May 2024
NCT01345175 (CTgov)	Phase 3	Rectal Cancer	69	Rifaximin (Pts Receiving Rifaximin)	lxauvuntiy = htluuwjkav kyageyxhrg (utgzlwntjl, rwrcxaxhwx - mjlpbeubgv) View more	-	14 May 2024
				Placebo (Pts Receiving Placebo)	lxauvuntiy = wepufinfdj kyageyxhrg (utgzlwntjl, dprbznhehl - rwzzxaibjb) View more
NCT05150587 (CTgov)	Phase 2	Rosacea	216	Rifaximin (Rifaximin 250 mg TID)	qvykhnnboi(jvgsykcasj) = yociugxxpd gtnlhapwur (mijnwxlgvf, 9.24) View more	-	24 Apr 2024
				Rifaximin (Rifaximin 500 mg TID)	qvykhnnboi(jvgsykcasj) = yjnrlwccua gtnlhapwur (mijnwxlgvf, 14.78) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Rifaximin

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation